EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ArriVent BioPharma's enterprise value is $431.38 Mil.
ArriVent BioPharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-39.83 Mil. Therefore, ArriVent BioPharma's EV-to-EBITDA for today is -10.83.
The historical rank and industry rank for ArriVent BioPharma's EV-to-EBITDA or its related term are showing as below:
AVBP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.11 Med: 0 Max: 0
Current: -10.83
AVBP's EV-to-EBITDA is ranked worse than 100% of 454
companies
in the Biotechnology industry
Industry Median: 10.055
vs AVBP: -10.83
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
ArriVent BioPharma EV-to-EBITDA Historical Data
The historical data trend for ArriVent BioPharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ArriVent BioPharma's EV-to-EBITDA
For the Biotechnology subindustry, ArriVent BioPharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ArriVent BioPharma's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ArriVent BioPharma's EV-to-EBITDA falls into.
ArriVent BioPharma's current Enterprise Value is $431.38 Mil.
ArriVent BioPharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ArriVent BioPharma's PE Ratio for today is calculated as:
ArriVent BioPharma's share price for today is $17.36.
ArriVent BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.114.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of ArriVent BioPharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
ArriVent BioPharma (ArriVent BioPharma) Business Description
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. They seek to utilize our team's deep drug development experience to maximize the potential of our lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVBP has been successfully added to your